A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines

被引:81
作者
Chay, CH
Cooper, CR
Gendernalik, JD
Dhanasekaran, SM
Chinnaiyan, AM
Rubin, MA
Schmaier, AH
Pienta, KJ
机构
[1] Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Med, Div Urol, Dept Surg, Ann Arbor, MI 48109 USA
[4] Thromgen Inc, Ann Arbor, MI USA
关键词
D O I
10.1016/S0090-4295(02)01969-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To identify genes important in prostate cancer metastatic to bone. Bone-specific metastasis is a common feature of prostate cancer and a significant cause of morbidity. Methods. To identify factors involved in organ-specific metastasis, we used cDNA microarray analysis to compare a bone-derived cell line, VCaP, with a soft tissue-derived cell line, DuCaP. Both cell lines were derived from the same patient and spontaneously passaged. Results. Forty-five genes were differentially expressed, and only seven of these also had increased expression in VCaP compared with normal prostatic tissue. Of these, protease-activated receptor I (PAR I) was verified as having increased expression by reverse transcriptase-polymerase chain reaction and Northern blot analysis, as well as by immunohistochemistry. PAR1 expression in a panel of prostate cancer cell lines demonstrated increased expression in those cell lines derived from bone metastases. Alpha-thrombin stimulation of the VCaP cells produced a dose-dependent mobilization of intracellular calcium compared with DuCaP, suggesting that PAR I expressed on the VCaP prostate cancer cell line is functional. Conclusions. These data indicate that a functional PARI is expressed on prostate cancer cell lines. The prostate cancer cell lines expressing PARI appear to have an association with increased bone metastases. (C) 2002, Elsevier Science Inc.
引用
收藏
页码:760 / 765
页数:6
相关论文
共 15 条
[1]   Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].
Bubendorf, L ;
Schöpfer, A ;
Wagner, U ;
Sauter, G ;
Moch, H ;
Willi, N ;
Gasser, TC ;
Mihatsch, MJ .
HUMAN PATHOLOGY, 2000, 31 (05) :578-583
[2]   Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray [J].
Bull, JH ;
Ellison, G ;
Patel, A ;
Muir, G ;
Walker, M ;
Underwood, M ;
Khan, F ;
Paskins, L .
BRITISH JOURNAL OF CANCER, 2001, 84 (11) :1512-1519
[3]   Thrombin signalling and protease-activated receptors [J].
Coughlin, SR .
NATURE, 2000, 407 (6801) :258-264
[4]   Delineation of prognostic biomarkers in prostate cancer [J].
Dhanasekaran, SM ;
Barrette, TR ;
Ghosh, D ;
Shah, R ;
Varambally, S ;
Kurachi, K ;
Pienta, KJ ;
Rubin, MA ;
Chinnaiyan, AM .
NATURE, 2001, 412 (6849) :822-826
[5]   Thrombin receptor overexpression in malignant and physiological invasion processes [J].
Even-Ram, S ;
Uziely, B ;
Cohen, P ;
Grisaru-Granovsky, S ;
Maoz, M ;
Ginzburg, Y ;
Reich, R ;
Vlodavsky, I ;
Bar-Shavit, R .
NATURE MEDICINE, 1998, 4 (08) :909-914
[6]  
FISCHER EG, 1995, CANCER RES, V55, P1629
[7]   Bradykinin and its metabolite, Arg-Pro-Pro-Gly. Phe, are selective inhibitors of alpha-thrombin-induced platelet activation [J].
Hasan, AAK ;
Amenta, S ;
Schmaier, AH .
CIRCULATION, 1996, 94 (03) :517-528
[8]   Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries [J].
Hasan, AAK ;
Schmaier, AH ;
Warnock, MA ;
Normolle, D ;
Driscoll, E ;
Lucchesi, BR ;
Werns, SW .
THROMBOSIS AND HAEMOSTASIS, 2001, 86 (05) :1296-1304
[9]   Role of thrombin receptor in breast cancer invasiveness [J].
Henrikson, KP ;
Salazar, SL ;
Fenton, JW ;
Pentecost, BT .
BRITISH JOURNAL OF CANCER, 1999, 79 (3-4) :401-406
[10]  
Korenchuk S, 2001, IN VIVO, V15, P163